AlzWell Revenue, Valuation & Funding (2024)

AlzWell generated an estimated $1.2M in annual revenue in 2024.

febohealth had no revenue at the time of the February 2022 interview. Focil stated plainly that the product is entirely free and that the company does not plan to generate revenue for approximately two to three years.

febohealth had approximately 14,000 downloads as of the February 2022 interview, accumulated entirely through organic growth since the App Store launch in June 2021. Focil estimated weekly downloads of approximately 200 at the time of the interview, extrapolating to roughly 800 downloads per month.

The app is free with no paid tier in place. Pricing was not discussed because the company has not yet begun monetization. Focil stated the company is targeting 100,000 users as the minimum threshold before introducing any revenue model. Customer segmentation by condition type, seats per account, and ARPU were not applicable or discussed given the pre-revenue stage.

febohealth operates on a free-user-growth model with no current monetization. Focil stated the company plans to begin generating revenue in two to three years, once it reaches a minimum of 100,000 users. The specific monetization mechanism after that threshold was not described in detail during the interview.

The company's cost-per-download benchmark is the national average of $2.80 per app download. Focil noted that prior advertising run through FOMAT had achieved a cost of approximately $1.70 per download, though he acknowledged the sample size was small and that formal paid advertising had only just launched as of February 1, 2022. Gross margin, burn rate, runway, churn, LTV, CAC, and conversion rate were not discussed, as the company has no revenue and had not yet run a meaningful paid acquisition campaign at the time of the interview.

Focil described the strategic rationale for raising outside capital despite having a well-funded parent agency: the SaaS model requires rapid growth and top talent, which he argued demands a different capital structure than the slower-moving clinical research business. The ESOP pool is set at 10 percent of the cap table, reserved for key employees.

Focil described having a team he characterized as top-notch, with members who share the company vision and have equity in the business. Specific headcount figures were not provided in the interview. The existence of an ESOP pool of 10 percent of the cap table indicates meaningful planned equity distribution to employees, but the number of current or planned employees was not stated.